NCT05894343View on ClinicalTrials.gov

Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 19, 2023

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2029

Conditions
Parkinson's Disease
Interventions
GENETIC

AAV-GAD

Bilateral infusion of AAV-GAD

Trial Locations (6)

10021

Weill Cornell Medicine, New York

10032

Columbia University Irving Medical Center, New York

19107

Thomas Jefferson University, Philadelphia

26506

West Virginia University, Morgantown

48322

Henry Ford West Bloomfield Hospital, West Bloomfield

06510

Yale University, New Haven

Sponsors

Lead Sponsor

MeiraGTx, LLC
All Listed Sponsors
lead

MeiraGTx, LLC

INDUSTRY

NCT05894343 - Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease | Biotech Hunter | Biotech Hunter